Skip to main content

Lexicon Pharmaceuticals, Inc.

LXRX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001062822

No open-market purchases or sales by Lexicon Pharmaceuticals, Inc. insiders were filed in the last 90 days; 149 institutions reported holding it in 13F filings for Q2 2026, worth $875.1M in total; no superinvestor holds it.

13F holders, Q1 2021

Institutional positions in Lexicon Pharmaceuticals, Inc. as of Mar 31, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
107
No complete 13F data for Q4 2020
Shares held
121.2M
No complete 13F data for Q4 2020
Total value
$711.5M
No complete 13F data for Q4 2020

Holders and value by quarter

Institutions reporting LXRX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ1 2021: 107 institutions
Q1 2021: 107 institutionsQ2 2021: 107 institutionsQ3 2021: 96 institutionsQ4 2021: 110 institutionsQ1 2022: 101 institutionsQ2 2022: 86 institutionsQ3 2022: 98 institutionsQ4 2022: 105 institutionsQ1 2023: 104 institutionsQ2 2023: 123 institutionsQ3 2023: 112 institutionsQ4 2023: 106 institutionsQ1 2024: 118 institutionsQ2 2024: 127 institutionsQ3 2024: 137 institutionsQ4 2024: 127 institutionsQ1 2025: 127 institutionsQ2 2025: 123 institutionsQ3 2025: 124 institutionsQ4 2025: 126 institutionsQ1 2026: 137 institutionsQ2 2026: 149 institutions
Value heldQ1 2021: $711.5M
Q1 2021: $711.5MQ2 2021: $540.2MQ3 2021: $583.0MQ4 2021: $478.9MQ1 2022: $251.3MQ2 2022: $221.0MQ3 2022: $357.3MQ4 2022: $280.5MQ1 2023: $353.8MQ2 2023: $438.2MQ3 2023: $205.8MQ4 2023: $279.8MQ1 2024: $417.8MQ2 2024: $471.0MQ3 2024: $453.1MQ4 2024: $220.1MQ1 2025: $122.5MQ2 2025: $242.9MQ3 2025: $344.4MQ4 2025: $299.5MQ1 2026: $504.5MQ2 2026: $875.1M
Institutions holding LXRX and their total value by quarter
QuarterHoldersValue
Q2 2026149$875.1M
Q1 2026137$504.5M
Q4 2025126$299.5M
Q3 2025124$344.4M
Q2 2025123$242.9M
Q1 2025127$122.5M
Q4 2024127$220.1M
Q3 2024137$453.1M
Q2 2024127$471.0M
Q1 2024118$417.8M
Q4 2023106$279.8M
Q3 2023112$205.8M
Q2 2023123$438.2M
Q1 2023104$353.8M
Q4 2022105$280.5M
Q3 202298$357.3M
Q2 202286$221.0M
Q1 2022101$251.3M
Q4 2021110$478.9M
Q3 202196$583.0M
Q2 2021107$540.2M
Q1 2021107$711.5M

Institutions, Q1 2021

Shares, value and share of portfolio for each institution holding Lexicon Pharmaceuticals, Inc..

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.

Institutions holding LXRX in Q1 2021
InstitutionSharesValue% of portfolioChange in sharesAction
D. E. Shaw & Co., Inc.3,006,612$17.6M0.02%––
BlackRock Inc.3,904,147$22.9M0.00%––
Vanguard Group Inc3,958,847$23.2M0.00%––
Ulys, L.L.C.4,321,214$25.4M100.00%––
BVF Inc8,394,000$49.3M1.85%––
FMR LLC9,102,838$53.4M0.00%––
Artal Group S.A.71,178,364$417.8M8.84%––